AbbVie Inc. (4AB.DE)
EUR 168.02
(0.36%)
EUR 168.02
(0.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.75 Billion USD | 13.98% |
| 2022 | 11.19 Billion USD | 42.3% |
| 2021 | 7.86 Billion USD | 1552.31% |
| 2020 | 476 Million USD | -96.33% |
| 2019 | 12.98 Billion USD | 103.4% |
| 2018 | 6.38 Billion USD | -33.45% |
| 2017 | 9.59 Billion USD | 2.22% |
| 2016 | 9.38 Billion USD | 24.51% |
| 2015 | 7.53 Billion USD | 120.96% |
| 2014 | 3.41 Billion USD | -39.78% |
| 2013 | 5.66 Billion USD | -2.63% |
| 2012 | 5.81 Billion USD | 60.66% |
| 2011 | 3.62 Billion USD | -23.24% |
| 2010 | 4.71 Billion USD | -4.36% |
| 2009 | 4.93 Billion USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 3.99 Billion USD | 42.89% |
| 2024 Q1 | 2.79 Billion USD | -12.43% |
| 2023 Q2 | 4.51 Billion USD | 63.04% |
| 2023 Q4 | 3.19 Billion USD | 40.07% |
| 2023 FY | 12.75 Billion USD | 13.98% |
| 2023 Q3 | 2.28 Billion USD | -49.46% |
| 2023 Q1 | 2.76 Billion USD | -28.49% |
| 2022 FY | 11.19 Billion USD | 42.3% |
| 2022 Q4 | 3.87 Billion USD | 39.85% |
| 2022 Q3 | 2.76 Billion USD | 13280.95% |
| 2022 Q2 | -21 Million USD | -100.7% |
| 2022 Q1 | 2.97 Billion USD | -41.29% |
| 2021 Q2 | 4.44 Billion USD | 8.24% |
| 2021 FY | 7.86 Billion USD | 1552.31% |
| 2021 Q3 | 4.3 Billion USD | -3.04% |
| 2021 Q4 | 5.07 Billion USD | 17.84% |
| 2021 Q1 | 4.1 Billion USD | 9.33% |
| 2020 FY | 476 Million USD | -96.33% |
| 2020 Q3 | 3.25 Billion USD | 332.85% |
| 2020 Q4 | 3.75 Billion USD | 15.3% |
| 2020 Q1 | 3.6 Billion USD | -8.92% |
| 2020 Q2 | 752 Million USD | -79.13% |
| 2019 Q4 | 3.95 Billion USD | 51.17% |
| 2019 Q2 | 3.4 Billion USD | 12.96% |
| 2019 FY | 12.98 Billion USD | 103.4% |
| 2019 Q1 | 3.01 Billion USD | 223.31% |
| 2019 Q3 | 2.61 Billion USD | -23.03% |
| 2018 Q1 | 2.9 Billion USD | 61.82% |
| 2018 Q2 | 2.76 Billion USD | -4.86% |
| 2018 FY | 6.38 Billion USD | -33.45% |
| 2018 Q3 | 3.15 Billion USD | 14.37% |
| 2018 Q4 | -2.44 Billion USD | -177.27% |
| 2017 Q3 | 2.7 Billion USD | 1.16% |
| 2017 FY | 9.59 Billion USD | 2.22% |
| 2017 Q4 | 1.79 Billion USD | -33.68% |
| 2017 Q1 | 2.41 Billion USD | 2.59% |
| 2017 Q2 | 2.67 Billion USD | 10.54% |
| 2016 Q1 | 2.27 Billion USD | 7.81% |
| 2016 FY | 9.38 Billion USD | 24.51% |
| 2016 Q3 | 2.36 Billion USD | -1.09% |
| 2016 Q2 | 2.38 Billion USD | 4.78% |
| 2016 Q4 | 2.35 Billion USD | -0.13% |
| 2015 Q3 | 1.88 Billion USD | 1.78% |
| 2015 Q2 | 1.85 Billion USD | 9.78% |
| 2015 Q1 | 1.68 Billion USD | 506.51% |
| 2015 Q4 | 2.11 Billion USD | 12.1% |
| 2015 FY | 7.53 Billion USD | 120.96% |
| 2014 Q1 | 1.35 Billion USD | -11.99% |
| 2014 Q3 | 1.21 Billion USD | -20.13% |
| 2014 Q4 | -415 Million USD | -134.3% |
| 2014 FY | 3.41 Billion USD | -39.78% |
| 2014 Q2 | 1.51 Billion USD | 12.14% |
| 2013 Q1 | 1.3 Billion USD | -28.33% |
| 2013 Q2 | 1.45 Billion USD | 11.34% |
| 2013 Q3 | 1.37 Billion USD | -5.64% |
| 2013 Q4 | 1.53 Billion USD | 11.96% |
| 2013 FY | 5.66 Billion USD | -2.63% |
| 2012 Q3 | 1.59 Billion USD | 12.24% |
| 2012 FY | 5.81 Billion USD | 60.66% |
| 2012 Q4 | 1.82 Billion USD | 14.09% |
| 2012 Q1 | 977.88 Million USD | -29.08% |
| 2012 Q2 | 1.42 Billion USD | 45.42% |
| 2011 Q4 | 1.37 Billion USD | 2471.84% |
| 2011 Q3 | 53.61 Million USD | -96.07% |
| 2011 Q2 | 1.36 Billion USD | 65.43% |
| 2011 Q1 | 824.43 Million USD | 0.0% |
| 2011 FY | 3.62 Billion USD | -23.24% |
| 2010 FY | 4.71 Billion USD | -4.36% |
| 2009 FY | 4.93 Billion USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bayer Aktiengesellschaft | -150 Million EUR | 8604.667% |
| Sanofi | 7.87 Billion EUR | -61.994% |